Skip to content
OpenCapital
Get started

Relmada Therapeutics, Inc. RLMD Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number at other companies

AMN Healthcare logo
AMN HealthcareAMN
304K+29.9%
Repligen logo
RepligenRGEN
116.8K—
The Baldwin Insurance Group, Inc. logo
The Baldwin Insurance Group, Inc.BWIN
1.7M+57.1%
Mondelez International logo
Mondelez InternationalMDLZ
6.6M+14.8%
Alto Ingredients, Inc. logo
Alto Ingredients, Inc.ALTO
1.3M-17.4%
Strattec Security logo
Strattec SecuritySTRT
49K-13.7%

Other financials

Income statement

See full
Operating income-$19.5M-6.8%
Net income-$19.1M-8.5%
EPS (diluted)-$0.22+62.1%

Balance sheet

See full
Cash & equivalents$9.8M+750%
Total debt$104.1M-40.4%
Total equity$218.7M+875%
Total assets$235.4M+750%

Cash flow

See full
Operating cash flow-$15.1M+16.6%

Valuation

See full
Market cap$677.17M+2,907%

Returns & leverage

See full
Return on equity-48.8%-20.0pp
Debt / equity0.9×0.0×
Current ratio18.3×+13.0×

Where this comes from

Reported directly by Relmada Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber.

The official record: Relmada Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Relmada Therapeutics, Inc.'s share based compensation arrangement by share based payment award equity instruments other than options nonvested number.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Relmada Therapeutics, Inc.'s share based compensation arrangement by share based payment award equity instruments other than options nonvested number?
Relmada Therapeutics, Inc. (RLMD) reported share based compensation arrangement by share based payment award equity instruments other than options nonvested number of $8.01M in Q1 2026.